| HOME >> BIOLOGY >> TECHNOLOGY |
N. BILLERICA, Mass., Sept. 20 /PRNewswire/ -- Seahorse Bioscience, Inc., the leading manufacturer of instruments and consumables for measuring cellular metabolism announced today that Chief Executive Officer, Jay Teich, will present at the 2010 UBS Global Life Sciences Conference on Tuesday, September 21, 2010 at 4:00 p.m. EDT at the Grand Hyatt Hotel in New York City. Mr. Teich will highlight the company's strategy for maintaining rapid growth of 85% CAGR in a new $1BB Life Science Cellular Bioenergetics market. "We believe that we are at the right place at the right time to ride a wave of interest in cell bioenergetics as it applies to Cancer, Obesity, Diabetes, Ageing and Cardiovascular function," proclaimed Mr. Teich. A live webcast of the conference can be viewed at http://cc.talkpoint.com/ubsx001/092110a_lv/ About Seahorse Bioscience Seahorse XF instruments are the new standard in cellular bioenergetic measurements. More than 600 scientists in 20 countries are utilizing the award-winning XF Analyzers to advance their research into the role of mitochondrial (dys)function and its implications in diseases. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, visit http://www.seahorsebio.com.Seahorse Bioscience, Inc.Media Contact: Cynthia EganPhone: 978.671.1610 
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News 
Seahorse Bioscience to Present at 2010 UBS Global Life Sciences Conference
'/>"/>SOURCE Seahorse Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009
2. Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
3. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
4. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
5. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board
8. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
9. Signum Biosciences Names Braham Shroot as Chief Executive Officer
10. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
11. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |